Home
Categories
EXPLORE
True Crime
Comedy
Society & Culture
Business
Sports
Technology
History
About Us
Contact Us
Copyright
© 2024 PodJoint
Podjoint Logo
US
00:00 / 00:00
Sign in

or

Don't have an account?
Sign up
Forgot password
https://is1-ssl.mzstatic.com/image/thumb/Podcasts125/v4/8d/b8/0f/8db80f81-2247-4672-914d-289f9cb6f61b/mza_3544939216694081436.jpg/600x600bb.jpg
The Long Run with Luke Timmerman
Timmerman Report
186 episodes
1 week ago
Art Krieg, founder and CEO of Zola Therapeutics, on developing innate immune system activators for cancer.
Show more...
Science
RSS
All content for The Long Run with Luke Timmerman is the property of Timmerman Report and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Art Krieg, founder and CEO of Zola Therapeutics, on developing innate immune system activators for cancer.
Show more...
Science
https://i1.sndcdn.com/avatars-000334687557-gwdmq9-original.jpg
Ep172: Mostafa Ronaghi on Studying Live Cells at Scale
The Long Run with Luke Timmerman
1 hour 20 minutes 53 seconds
9 months ago
Ep172: Mostafa Ronaghi on Studying Live Cells at Scale
Mostafa Ronaghi, co-founder and executive board member of Cellanome, on developing technology to look at live cells and cellular interactions at scale.
The Long Run with Luke Timmerman
Art Krieg, founder and CEO of Zola Therapeutics, on developing innate immune system activators for cancer.